Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Mushroom supplement tested for gut health and mood boost

NCT ID NCT07027462

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested whether a mushroom blend can help with occasional stomach issues like bloating and constipation, and also improve mood. Forty healthy adults aged 30 to 60 who sometimes had digestive discomfort took either the mushroom supplement or a placebo. Researchers checked changes in gut bacteria, digestion symptoms, and mood over time.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
mushroom blend
What this could lead to
If it works, this could point toward a natural supplement to ease occasional bloating, gas, or constipation and improve mood.
What could go wrong
This is a small, early study in healthy people, so results may not apply to others. The supplement may have no real benefit over placebo.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

40 people

The number who actually took part.

Started

Jun 2025

Finished

Mar 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

30 to 60 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Healthy males and females aged 30 to 60 years of age (inclusive). * Subject has provided written and dated informed consent. * Individual indicates they experience occasional GI discomfort, and have never been diagnosed with any gastrointestinal disorder, yet have occasional complaints of bowel irregularity, bloating or discomfort (after meals or beverages). * Subject may express that they experience occasional after-snack or a meal, intestinal gas-related symptoms including abdominal discomfort, cramps, distended feeling/bloating, and or flatulence as part of the study entry criteria. * Occasional GI distress will be defined as \< 3 times per week over the prior 6 weeks, with each episode resolving within 24 hours and not requiring medical intervention. * Body Mass Index (BMI) 19 to 34.9 kg/m2 (normal weight to class I obesity) * Subject is a non-smoker. * Subject agrees to not use any new vitamin, mineral, or other dietary supplement product until after study completion. * Subject agrees to provide a stool sample for microbiota analysis per the study protocol. * Subject is willing and able to comply with the protocol and the scheduled study visits. * Subject will be asked about dietary supplementation use within the past 6 months. * If subject began taking a supplement within the past month, participant will be asked to discontinue supplement use followed by a 2-week washout prior to participation. * In all other cases, supplement use will be asked to be maintained throughout the study. Exclusion Criteria: * Subject has any of the following medical conditions: * Gastrointestinal disease or any GI diagnosed disorder (i.e., dyspepsia, functional dyspepsia, gastrointestinal reflux, etc.) * active heart disease * uncontrolled high blood pressure (≥ 140/90 mmHg) * renal or hepatic impairment/disease * Type I or II diabetes * bipolar disorder * Parkinson's disease * unstable thyroid disease * immune disorder (such as HIV/AIDS) * Any medical condition deemed exclusionary by the Principal Investigator (PI) * Subject has a history of cancer (except localized skin cancer without metastases) within 5 years prior to screening. * Subject is currently taking any blood thinners. * Subject has a medical condition that is known to impact the gastrointestinal system and functions. * Subject is currently taking or has within the prior 120 days any prescription antibiotics, or supplemental probiotic or prebiotics (30-day washout is acceptable). * Subject is currently taking supplemental (OTC medicine or dietary supplements) of any laxative or bowel function stimulant \[i.e., Ri-Mucil, Metamucil (psyllium), Colace, Milk of Magnesia, MiraLAX, FiberCon (polycarophil), DulcoLax, etc.\] * Subject is on an unstable dose of medication (defined as fewer than 90 days at the same dose). * Subject is taking a prescription medication deemed exclusionary by the Principal Investigator (PI). * Subject has an allergy to any ingredients in the Study Product. * Subject has a history of drug or alcohol abuse in the past 12 months. * Subject has a history of a psychiatric illness or mental health disorder (including for drug or alcohol treatment) that required hospitalization in the prior 12 months. * Subject has any condition or health history abnormality that in the expert opinion of the PI, participation in the study would compromise the safety of the subject or the quality of the study data. * The subject is participating in or has participated in another clinical research study within 30 days prior to the Screening visit. * Subject is consuming any of the study products already. * Subject is diagnosed with a stress-disorder.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Healthy are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • University of South Carolina Sport Science Lab

    Columbia, South Carolina, 29208, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.